Madrigal Pharmaceuticals (MDGL) Stock

Wall Street analysts have set an average price target for Madrigal (MDGL) that suggests a possible increase of 26.4%. Although the reliability of this popular measure is debatable, the recent positive changes in earnings estimates could lead to a rise in the stock's value.

This company has a promising future. There are many opportunities for growth and success. Exciting times are coming for them.

Is Madrigal (MDGL) a strong choice for momentum investors? Let's take a closer look.

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced that it will take part in discussions at three upcoming investor conferences.

Madrigal Pharmaceuticals' Rezdiffra has received FDA approval and is being well-received in the market, making it a key treatment for NASH with advanced fibrosis. The wide insurance coverage and the option for non-invasive testing improve access for patients and help increase the use of Rezdiffra. Although there is competition from Novo Nordisk's Semaglutide, Rezdiffra's focus on the liver gives it a unique benefit.

MDGL stock has risen after the company announced third-quarter results that exceeded expectations, surpassing both earnings and revenue forecasts. This positive performance was mainly due to strong sales of Rezdiffra.

Madrigal (MDGL) reported a quarterly loss of $4.92 per share, which is better than the Zacks Consensus Estimate of a loss of $6.94. This is an improvement compared to a loss of $5.34 per share from the same period last year.

CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing new treatments for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH), has announced that it will present several data on resmetirom at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, scheduled for November 15-19, 2024, in San Diego.

Madrigal Pharmaceuticals' Rezdiffra, which has been approved for NASH, is experiencing high demand and increasing revenue, suggesting that the Q3 earnings report could impact the stock price. Although the company faced significant losses in Q2, its $1.1 billion in cash and effective strategy make Rezdiffra a top contender in the NASH/MASH market. Analysts predict that Madrigal will see considerable revenue growth and reduced losses, with hopes of becoming profitable in the next few years.